Results 221 to 230 of about 36,304 (249)

Incretin-Based Therapies

Medical Clinics of North America, 2015
Incretin-based therapies are steadily gaining clinical popularity, with many more products in the developmental pipeline. Current treatment recommendations incorporate GLP-1 RAs and DPP-4 inhibitors as important agents for consideration in the treatment of T2DM owing to their low hypoglycemia risk, ability to address postprandial hyperglycemia (DPP-4 ...
openaire   +2 more sources

Incretins and Lipid Metabolism

Current Medicinal Chemistry, 2018
Background: Recent findings indicate that incretin hormones and incretin-based therapies may affect the metabolism of lipoproteins, although the corresponding mechanisms are not clearly defined. Objective: To summarize the available data on the mechanisms linking incretins with the characteristics of serum lipoproteins and discuss the clinical ...
Vasilis, Tsimihodimos, Moses, Elisaf
openaire   +2 more sources

[Incretin and incretin-based therapies].

Nihon rinsho. Japanese journal of clinical medicine, 2010
GIP and GLP-1 are major incretins and secreted from K-cell and L-cell in response to meal ingestion, respectively. GIP and GLP-1 potentiate glucose-induced insulin secretion by binding GIP receptor and GLP-1 receptor, respectively, on pancreatic beta-cell and increasing intracellular cAMP concentration (incretin effect). GIP receptor and GLP-1 receptor
Norio, Harada, Nobuya, Inagaki
openaire   +1 more source

Cardiovascular benefits of incretins

BMJ, 2013
Cohen and colleagues make no mention of the evidence that treatment of type 2 diabetes with increasingly larger doses of sulfonylureas and insulin is not without serious risk from hypoglycaemia, weight gain, and possibly increased cardiovascular risk.1 A balanced account of this is needed in any review of incretins.
Anthony H, Barnett, Paul, O'Hare
openaire   +2 more sources

[Incretins].

Vnitrni lekarstvi, 2007
Insulin secretion is greater after peroral challenge than after intravenous glucose administration due to so-called incretin effect. The major incretins are glucagon-like peptide 1 and glucose-dependent-insulinotropic peptide. Physiology, pathophysiology and therapeutic implications of incretins in diabetes, neurodegenerative disorders and stress ...
J, Vrbíková, K, Vondra
openaire   +1 more source

Pleiotropic effects of incretins and antidiabetics with incretine mechanism

Orvosi Hetilap, 2013
Discovery of physiological and pharmacological characteristics of incretins (glucagon-like peptide-1 and glucose-dependent insulinotrop polypeptide), and the introduction of various products of those into the clinical practice has fundamentally changed blood glucose lowering therapy in type 2 diabetes.
openaire   +2 more sources

The physiology of incretins

Orvosi Hetilap, 2011
The discovery of incretins − glucagon-like peptide (GLP)-1 and glucose-dependent insulinotrop peptide (GIP) −, clarification of their physiological properties as well as therapeutic application of incretin-based blood glucose lowering drugs opened new perspectives in the medical management of type 2 diabetes.
openaire   +2 more sources

Incretins

RCSB Protein Data Bank, 2023
Jennifer Jiang, Shuchismita Dutta
openaire   +1 more source

GLUCOREGULATORY ACTIONS OF INCRETINS/ANTI-INCRETINS

Diabetes mellitus (DM) is a chronic debilitating and non-communicable disease characterized by chronic hyperglycemia and resulting from a defect in insulin secretion, insulin action, or both. Apart from these, defective actions of the gastrointestinal (GI) incretin hormones: glucagon-like peptide–1 (GLP-1) and glucose-dependent insulinotropic ...
openaire   +1 more source

Understanding incretins

Intensive Care Medicine, 2014
Adam M, Deane, Palle B, Jeppesen
openaire   +2 more sources